Latest Medicine stories from Life.
Strategic angle: A groundbreaking approach using CRISPR technology shows promise in treating heart failure by enhancing mitochondrial function.
Strategic angle: Researchers discover new functions of the cereblon protein that could enhance cancer drug efficacy.
Strategic angle: Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news
Servier's acquisition of Day One Biopharmaceuticals for $2.5 billion could reshape its position in the pediatric oncology market, but risks remain.
Strategic implications in focus: China has approved a new obesity treatment from Pfizer, heightening competition in a market poised to become even more crowded.